A bruised Circassia offloads debt by returning COPD drugs to AstraZeneca
It had a glittering £200 million mega-IPO on the London Stock Exchange in 2014, but failure after trial failure blighted its prospects. A battered Circassia …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
